Physician profile
Brett Emerson Fortune
NPI 1720121585
$147,493.90
in general payments reported to CMS, 2019-2025
20 companies · $57K in 2025
The $57K reported for 2025 was more than what 86% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $16K · 2021: $6,264 · 2022: $3,263 · 2023: $9,424 · 2024: $28K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Consulting Fee: $38K · Travel and Lodging: $5,409 · Food and Beverage: $3,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,203.81 |
| Consulting Fee | $37,520.00 |
| Travel and Lodging | $5,409.47 |
| Food and Beverage | $3,964.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $46,449.87 | 2019-2025 | Viatorr Endoprosthesis, Gore Viatorr Tips Endoprosthesis, Gore Viatorr Tips Endoprosthesis With Controlled Expansion |
| Novo Nordisk INC | $34,677.56 | 2024-2025 | Wegovy |
| Madrigal Pharmaceuticals | $20,456.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Becton, Dickinson and Company | $9,288.55 | 2019 | |
| Bard Peripheral Vascular, INC. | $8,905.87 | 2024-2025 | Liverty |
| Dova Pharmaceuticals | $6,889.04 | 2019-2020 | |
| Wilson Cook Medical Incorporated | $6,462.50 | 2020-2021 | |
| Gilead Sciences, INC. | $4,943.94 | 2019-2025 | Livdelzi, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,688.43 | 2019-2024 | Xifaxan |
| Bausch Health US, LLC | $3,653.54 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $244.54 | 2019 | |
| Mirum Pharmaceuticals, INC. | $195.81 | 2024-2025 | Livmarli, Volixibat, Cholbam |
| Mallinckrodt Hospital Products INC. | $192.06 | 2023-2025 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $143.91 | 2019-2020 | |
| Cook Medical LLC | $128.36 | 2024 | Echotip Insight |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $125.00 | 2021 | |
| Kamada Ltd. | $47.99 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Fortune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.